title: [Observations of MDPV users: a prospective-retrospective study].
abstract: BACKGROUND
  The spreading of "designer drugs" resulted in the appearance of "similar yet different" substances, the chemical structure of which are modified so regularly, which makes their research very difficult. We came across one of these substances, MDPV, while on night duty before it was mentioned in research papers. Our own research explores the changes in drug consumption patterns, especially in MDPV consumption patterns in the past few years, and gives a description of psychiatric and associated symptoms.
  
  
  METHODS
  We compared cases of patients admitted to our ward between Jan 1., 2010 and November 30., 2012 with symptoms of drug consumption and its complications (BNO F15.00-F15.90, F19.00-F19.90). We examined symptoms that required inpatient care at the psychiatry ward.
  
  
  RESULTS
  While in 2010 we treated only 3 MDPV users on 6 occasions, 4 Mephedrone users on 6 occasions, and 9 patients using other substances (Speed, Cannabis) on 10 occasions at our ward, in 2011 there were no Mephedrone-related hospitalizations and only 9 patients using other substances (Cannabis, Synthetic Cannabinoid, 5-MeO-AMT, Glue, Metamizole, Ketamine) were treated on 13 occasions. Between Jan 1. 2011. and Nov 30.2012 there were 40 recorded cases related to MDPV-use in the period: forty people were registered on 87 occasions. Nine people receive impatient care after observation on 10 occasions. In all these cases psychotic symptoms were recorded.
  
  
  CONCLUSIONS
  The constant development of designer drugs requires better administration of the individual cases, symptoms and forms of treatments. Informing doctors about these details also seems necessary. We have found that the behaviours of drug users show a positive correspondence with changing legal environments, which calls for a more sensible drug-related policy.
authors.affiliation: Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Pszichiátriai Tanszék, Debrecen, Hungary. gaborandrassy@hotmail.com
authors.forename: Gábor
authors.initials: G
authors.lastname: Andrássy
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Asztalos
authors.forename: Anikó
authors.initials: A
authors.lastname: Égerházi
authors.forename: Ede
authors.initials: E
authors.lastname: Frecska
mesh_terms: D052117:Benzodioxoles; D002188:Cannabis; D015198:Designer Drugs; D004177:Dipyrone; D055030:Drug Users; D005260:Female; D006760:Hospitalization; D006801:Humans; D007649:Ketamine; D008297:Male; D008694:Methamphetamine / Q000031:analogs & derivatives*; D011446:Prospective Studies; D011567:Psychiatric Department, Hospital; D011619:Psychotropic Drugs; D011759:Pyrrolidines; D012189:Retrospective Studies; D015813:Substance Abuse Detection; D000094982:Synthetic Cathinone
chemical_list: D052117:Benzodioxoles; D015198:Designer Drugs; D011619:Psychotropic Drugs; D011759:Pyrrolidines; D008694:Methamphetamine; D004177:Dipyrone; D007649:Ketamine; C548233:mephedrone; D000094982:Synthetic Cathinone